Compare Cassava Sciences Inc (FLNA) vs Lamb Weston Holdings Inc (LW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs Lamb Weston Holdings Inc — how do they compare? Cassava Sciences Inc trades at $0.83 (market cap $39.40M), while Lamb Weston Holdings Inc trades at $49.24 (market cap $6.81B). The key difference: Lamb Weston Holdings Inc is far larger — about 172.8× Cassava Sciences Inc's market cap, and Lamb Weston Holdings Inc pays a 3.07% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Cassava Sciences Inc for 37 Days and Lamb Weston Holdings Inc for 66 Days on average.
| FLNA | LW | |
|---|---|---|
Market Cap | $39.40M | $6.81B |
Volume | 759,018 | 4,638,686 |
Sector | Health | Consumer Staples |
52-Week High | $4.64 | $66.57 |
52-Week Low | $0.68 | $38.48 |
Typical Hold Time | 37 Days | 66 Days |
Enterprise Value | -$43.28M | $10.61B |
Dividend Yield | — | 3.07% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $0.8157, down 6.77% today, with a bearish technical signal from moving averages. The company shows improving quarterly EPS trends, beating expectations in recent quarters, though it remains unprofitable with negative ROE and ROA. Recent FDA clearance for its epilepsy drug trial provides a positive catalyst. Analyst sentiment is bullish with 67% buy ratings.
The outlook hinges on clinical progress; upside exists if Phase 2a trials succeed, but high cash burn and lack of revenue pose significant risks. Investors should weigh the strong analyst support against the company's financial challenges and binary clinical outcomes.
Lamb Weston (LW) trades at $48.09, up 0.38% on the day, with a bullish technical signal and consistent earnings beats in recent quarters. The stock shows strong profitability with a 14.17% ROE and trades at a P/E of 26.28. Recent news highlights cost savings exceeding $100 million and positive analyst sentiment for upcoming earnings. Support is firm at $48, aligning with the current price, while resistance sits at $49 and $50.
The outlook is cautiously optimistic given earnings momentum and analyst consensus, but risks include margin pressure from rising costs and competitive threats. The consensus price target of $53.71 suggests upside potential, though net income decline from $1.0B in 2023 to $357M in 2025 warrants monitoring operational efficiency.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About Lamb Weston Holdings Inc
Lamb Weston is the world's second-largest producer of branded and private-label frozen potato products, such as French fries, sweet potato fries, tater tots, diced potatoes, mashed potatoes, hash browns, and chips. The company also has a small appetizer business that produces onion rings, mozzarella sticks, and cheese curds. Including joint ventures, 63% of fiscal 2022 revenue was U.S.-based, with the remainder stemming from Europe, Canada, Japan, China, Korea, Mexico, and several other countries. Lamb Weston's customer mix is estimated 58% quick-serve restaurants, 19% full-service restaurants, 8% other food services (hotels, commercial cafeterias, arenas, schools), and 16% retail. Lamb Weston became an independent company in 2016 when it was spun off from Conagra.
Read more on LW →
